医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2014年
25期
88-88
,共1页
不同剂量%阿托伐他汀%脑梗死%应用探讨
不同劑量%阿託伐他汀%腦梗死%應用探討
불동제량%아탁벌타정%뇌경사%응용탐토
Different dose%Atorvastatin%Cerebral infarction%Application
目的探讨不同剂量阿托伐他汀在治疗脑梗死患者中临床疗效。方法随机选取我院近年来收治的120例脑梗死患者,随机分为A、B、C三组,每组40例,A组：采取常规治疗。 B、C组：在A组治疗的基础上,分别服用阿托伐他汀10mg/d、20mg/d治疗。2w后观察每组血脂、血清hs-CRP及神经功能的改善程度。结果治疗后,B、C组在改善血脂水平及血清hs-CRP方面均显著优于A组,且C组效果更好；C组的NIHSS评分也显著低于B组,差异具有统计学意义(<0.05)。结论阿托伐他汀在治疗急性脑梗时,具有较好的临床疗效,且20mg治疗效果更佳。
目的探討不同劑量阿託伐他汀在治療腦梗死患者中臨床療效。方法隨機選取我院近年來收治的120例腦梗死患者,隨機分為A、B、C三組,每組40例,A組：採取常規治療。 B、C組：在A組治療的基礎上,分彆服用阿託伐他汀10mg/d、20mg/d治療。2w後觀察每組血脂、血清hs-CRP及神經功能的改善程度。結果治療後,B、C組在改善血脂水平及血清hs-CRP方麵均顯著優于A組,且C組效果更好；C組的NIHSS評分也顯著低于B組,差異具有統計學意義(<0.05)。結論阿託伐他汀在治療急性腦梗時,具有較好的臨床療效,且20mg治療效果更佳。
목적탐토불동제량아탁벌타정재치료뇌경사환자중림상료효。방법수궤선취아원근년래수치적120례뇌경사환자,수궤분위A、B、C삼조,매조40례,A조：채취상규치료。 B、C조：재A조치료적기출상,분별복용아탁벌타정10mg/d、20mg/d치료。2w후관찰매조혈지、혈청hs-CRP급신경공능적개선정도。결과치료후,B、C조재개선혈지수평급혈청hs-CRP방면균현저우우A조,차C조효과경호；C조적NIHSS평분야현저저우B조,차이구유통계학의의(<0.05)。결론아탁벌타정재치료급성뇌경시,구유교호적림상료효,차20mg치료효과경가。
Objective To investigate the effects of dif erent doses of atorvastatin in the treatment of cerebral infarction in patients with clinical ef icacy. Methods In our hospital in recent years treated 120 cases with cerebral infarction were randomly divided into A, B, C3 group, 40 cases in each group, group A: take the conventional treatment. B, C group: A group based on the treatment of atorvastatin, respectively 10mg / d, 20mg / d treatment. Degree of improvement were observed after 2 weeks of blood lipid, serum hs-CRP and neural function. Results After the treatment, B, C group in improvement of blood lipid level and serum hs-CRP were significantly better than those in A group, and C group was best; group C NIHSS score was significantly lower than that of B group (P<0.05). Conclusion Atorvastatin in the treatment of acute cerebral infarction, the clinical ef icacy is good, and bet er therapeutic ef ect of 20mg.
